Supported By Novartis Pharmaceuticals Corporation, Rigel Pharmaceuticals, Inc.
Room 30DE, San Diego Convention Center

Program Description

This CME-certified satellite symposium held in conjunction with the 2024 World Lung Cancer Conference, titled Lung Cancer Tumor Board®: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection will gather leading lung cancer experts to engage in an interactive discussion on targeted treatment strategies for real-world clinical scenarios. The symposium will explore pivotal advancements and emerging clinical data that could further transform treatment paradigms in lung cancer care specifically in the patients with alterations in MET, RET and KRAS.

Speakers

Charu Aggarwal MD, MPH
Presenter
Penn Center for Cancer Care Innovation
Precision Oncology Innovation
Director
Philadelphia, PA